On 26 February 2026, Shenzhen Bay Laboratory and China Resources Sanjiu formally signed an agreement in Shenzhen to establish the‘Joint Research Centre for Brain Science and Neurological Diseases’. Representatives from both institutions attended the ceremony, including NiengYan, Director of Shenzhen Bay Laboratory; HuaweiQiu, Chairman of China Resources Sanjiu; HuanTu, Deputy Director of the Laboratory; WenbiaoGan, Director of the Institute of Neurological and Psychiatric Disorders; LiangWang, Vice President of China Resources Sanjiu; and YongWang, General Manager of the R&D CentreofChina Resources Sanjiu.

As China's ageing population accelerates, the incidence of central nervous system degenerative diseases such as Alzheimer's and Parkinson's continues to rise. Concurrently, associated neuropsychiatric issues including sleep disorders, cognitive decline, and emotional disturbances are becoming increasingly prominent. These conditions share common challenges: difficulty in early diagnosis, limited effective interventions, high long-term treatment costs, and significant family caregiving burdens. They have become major obstacles affecting the health and quality of life of the elderly population, necessitating more efficient and accessible diagnostic, therapeutic, and intervention solutions across society.

Brain science and neuropsychiatric disorders constitute a key research domain for both the Shenzhen Bay Laboratory and the Shenzhen Medical Academy of Research and Translation. The two institutions are jointly committed to attracting global talent and establishing a comprehensive innovation chain spanning fundamental research to translational outcomes.

NiengYanstated that the laboratory possesses distinct advantages in disease mechanism research, novel target identification, and early-stage drug development, while China Resources Sanjiu demonstrates robust capabilities in industrial transformation and commercialisation. The complementary strengths of both parties will establish a model for industry-academia-research collaboration, accelerating the implementation of research outcomes to benefit patients.

HuaweiQiuremarked that the joint research centre carries profound expectations in serving the national health strategy. As a central state-owned enterprise serving the national economy and people's livelihoods, China Resources Sanjiu will leverage this platform to focus on breakthroughs in key technologies and clinical translation within the field of neurological diseases. By integrating superior resources to establish an industry-academia-research collaborative system, it aims to tangibly enhance the health standards of the entire population.